{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T02:16:35Z","timestamp":1790388995410,"version":"4.1.0"},"reference-count":51,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T00:00:00Z","timestamp":1752710400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Morinomiyako Medical Research Foundation","award":["J23032A010"],"award-info":[{"award-number":["J23032A010"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>Data on the clinical effectiveness and adverse events of daptomycin in pediatric patients, considering dosage and renal function, are limited.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Aim<\/jats:title>\n<jats:p>In this study, we aimed to investigate the clinical effectiveness of daptomycin, incidence of related adverse events, and associations between clinical outcomes and risk factors, including dosage and renal function, in pediatric patients.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Methods<\/jats:title>\n<jats:p>Medical records of pediatric patients treated with daptomycin between September 2011 and December 2022, were retrospectively reviewed. Clinical effectiveness was categorized as cure, improvement, failure, or non-evaluable. The clinical success rate was defined as the sum of cured and improved cases. We classified doses based on the approved ranges: underdose (&gt;1\u2009mg\/kg less than the approved dose), adequate dose (approved dose \u00b11\u2009mg\/kg), and overdose (&gt;1\u2009mg\/kg more than the approved dose). Obesity was defined as a body mass index\u2009\u2265\u200930\u2009kg\/m<jats:sup>2<\/jats:sup>, with adjusted body weight used for dosing in these patients.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Findings<\/jats:title>\n<jats:p>We enrolled 54 patients, achieving a clinical success rate of 91%. Four (7%) patients died, particularly those with microbiological failure (<jats:italic>P<\/jats:italic>\u2009=\u20090.004) and underdosing (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001). The underdose group comprised a higher proportion of younger patients (<jats:italic>P<\/jats:italic>\u2009=\u20090.020). Additionally, seven (13%) patients experienced daptomycin-related adverse events, including creatine phosphokinase elevation, eosinophilic pneumonia, rhabdomyolysis, liver failure, and drug fever, occurring regardless of renal function. Five patients received an approved dose, while two received an overdose.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec005\">\n<jats:title>Conclusion<\/jats:title>\n<jats:p>Adequate daptomycin dosing improved clinical effectiveness and the mortality rate. However, continuous monitoring of adverse events remains critical for patients receiving the approved dose, including those with a normal renal function.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0327993","type":"journal-article","created":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T17:37:39Z","timestamp":1752773859000},"page":"e0327993","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":3,"title":["Influence of renal function and daptomycin dose on clinical effectiveness and adverse events in Japanese pediatric patients: A multicenter retrospective observational study"],"prefix":"10.1371","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1190-6540","authenticated-orcid":true,"given":"Chihiro","family":"Shiraishi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5272-9560","authenticated-orcid":true,"given":"Hideo","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Hirai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoya","family":"Nishiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Inagaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Ashizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Nakamatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuko","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Miyagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Honda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Kakiuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayumi","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Tashiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Izumikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mao","family":"Hagihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhiro","family":"Asai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuaki","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshige","family":"Mikamo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Iwamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,7,17]]},"reference":[{"issue":"5","key":"pone.0327993.ref001","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.ijantimicag.2014.01.018","article-title":"Daptomycin activity tested against 164457 bacterial isolates from hospitalised patients: summary of 8 years of a Worldwide Surveillance Programme (2005-2012)","volume":"43","author":"HS Sader","year":"2014","journal-title":"Int J Antimicrob Agents"},{"issue":"3","key":"pone.0327993.ref002","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1093\/cid\/cir034","article-title":"Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary","volume":"52","author":"C Liu","year":"2011","journal-title":"Clin Infect Dis"},{"issue":"5","key":"pone.0327993.ref003","first-page":"282","article-title":"Prescribing trends with daptomycin (cubicin) for the treatment of gram-positive infections","volume":"33","author":"NH Chan Tompkins","year":"2008","journal-title":"P T"},{"issue":"6","key":"pone.0327993.ref004","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1093\/jac\/dkn372","article-title":"Daptomycin versus vancomycin plus gentamicin for treatment of bacteraemia and endocarditis due to Staphylococcus aureus: subset analysis of patients infected with methicillin-resistant isolates","volume":"62","author":"SJ Rehm","year":"2008","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"pone.0327993.ref005","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1093\/cid\/cir764","article-title":"Daptomycin versus vancomycin for bloodstream infections due to methicillin-resistant Staphylococcus aureus with a high vancomycin minimum inhibitory concentration: a case-control study","volume":"54","author":"CL Moore","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"7","key":"pone.0327993.ref006","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa053783","article-title":"Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus","volume":"355","author":"VG Fowler","year":"2006","journal-title":"N Engl J Med"},{"issue":"15","key":"pone.0327993.ref007","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1093\/ajhp\/zxab123","article-title":"Validity of 2020 vancomycin consensus recommendations and further guidance for practical application","volume":"78","author":"MJ Rybak","year":"2021","journal-title":"Am J Health Syst Pharm"},{"key":"pone.0327993.ref008","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofx162.074","article-title":"The emperor\u2019s new clothes: prospective observational evaluation of the association between the day 2 vancomycin exposure and failure rates among adult hospitalized patients with MRSA bloodstream infections (PROVIDE)","volume":"4","author":"TP Lodise","year":"2017","journal-title":"Open Forum Infect Dis"},{"issue":"2","key":"pone.0327993.ref009","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1093\/cid\/ciu444","article-title":"Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America","volume":"59","author":"DL Stevens","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"44","key":"pone.0327993.ref010","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1093\/eurheartj\/ehv319","article-title":"2015 ESC Guidelines for the management of infective endocarditis: the task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM)","volume":"36","author":"G Habib","year":"2015","journal-title":"Eur Heart J"},{"key":"pone.0327993.ref011","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s13017-018-0219-9","article-title":"2018 WSES\/SIS-E consensus conference: recommendations for the management of skin and soft-tissue infections","volume":"13","author":"M Sartelli","year":"2018","journal-title":"World J Emerg Surg"},{"issue":"3","key":"pone.0327993.ref012","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2016-2477","article-title":"Daptomycin for complicated skin infections: a randomized trial","volume":"139","author":"J Bradley","year":"2017","journal-title":"Pediatrics"},{"issue":"9","key":"pone.0327993.ref013","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1097\/INF.0000000000001926","article-title":"Randomized multicenter study comparing safety and efficacy of daptomycin versus standard-of-care in pediatric patients with staphylococcal bacteremia","volume":"37","author":"AC Arrieta","year":"2018","journal-title":"Pediatr Infect Dis J"},{"issue":"6","key":"pone.0327993.ref014","doi-asserted-by":"crossref","first-page":"581","DOI":"10.2174\/1389200215666140605130935","article-title":"A 30-years review on pharmacokinetics of antibiotics: is the right time for pharmacogenetics?","volume":"15","author":"L Baietto","year":"2014","journal-title":"Curr Drug Metab"},{"issue":"12","key":"pone.0327993.ref015","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1186\/2047-783X-15-12-533","article-title":"Comparison of the pharmacokinetic properties of vancomycin, linezolid, tigecyclin, and daptomycin","volume":"15","author":"KS Estes","year":"2010","journal-title":"Eur J Med Res"},{"issue":"1","key":"pone.0327993.ref016","article-title":"Body composition during growth. In vivo measurements and biochemical data correlated to differential anatomical growth","volume":"47","author":"B Friis-Hansen","year":"1971","journal-title":"Pediatrics"},{"issue":"14","key":"pone.0327993.ref017","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.2146\/ajhp130601","article-title":"Daptomycin use in pediatric patients","volume":"71","author":"C Durand","year":"2014","journal-title":"Am J Health Syst Pharm"},{"issue":"3","key":"pone.0327993.ref018","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.jiac.2021.11.019","article-title":"Efficacy and safety of daptomycin in Japanese pediatric participants with complicated skin and soft tissue infections or bacteremia caused by gram-positive cocci","volume":"28","author":"S Iwata","year":"2022","journal-title":"J Infect Chemother"},{"issue":"3","key":"pone.0327993.ref019","first-page":"175","article-title":"Key potentially inappropriate drugs in pediatrics: the KIDs list","volume":"25","author":"RS Meyers","year":"2020","journal-title":"J Pediatr Pharmacol Ther"},{"key":"pone.0327993.ref020","year":"2019"},{"issue":"1","key":"pone.0327993.ref021","doi-asserted-by":"crossref","first-page":"102501","DOI":"10.1016\/j.jiac.2024.08.016","article-title":"Association between age and onset of daptomycin-induced adverse events using the U.S. food and drug administration adverse event reporting system","volume":"31","author":"C Shiraishi","year":"2025","journal-title":"J Infect Chemother"},{"key":"pone.0327993.ref022","doi-asserted-by":"crossref","first-page":"838599","DOI":"10.3389\/fphar.2022.838599","article-title":"Physiologically based pharmacokinetic modeling of daptomycin dose optimization in pediatric patients with renal impairment","volume":"13","author":"L Ye","year":"2022","journal-title":"Front Pharmacol"},{"key":"pone.0327993.ref023","first-page":"2049936118820230","article-title":"Daptomycin dosing in obese patients: analysis of the use of adjusted body weight versus actual body weight","volume":"6","author":"AN Fox","year":"2019","journal-title":"Ther Adv Infect Dis"},{"issue":"9","key":"pone.0327993.ref024","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1093\/cid\/ciy287","article-title":"Effect of statin coadministration on the risk of daptomycin-associated myopathy","volume":"67","author":"RK Dare","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"3","key":"pone.0327993.ref025","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1111\/bcp.15063","article-title":"Factors affecting creatine phosphokinase elevation during daptomycin therapy using a combination of machine learning and conventional methods","volume":"88","author":"S Imai","year":"2022","journal-title":"Br J Clin Pharmacol"},{"issue":"9","key":"pone.0327993.ref026","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1093\/ndt\/gfs611","article-title":"Pre-dialysis chronic kidney disease in children: results of a nationwide survey in Japan","volume":"28","author":"K Ishikura","year":"2013","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"pone.0327993.ref027","first-page":"7","article-title":"Daptomycin use in neutropenic patients with documented gram-positive infections","volume":"22","author":"KVI Rolston","year":"2014","journal-title":"Support Care Cancer"},{"key":"pone.0327993.ref028","author":"CUBICIN\u00ae (Daptomycin for Injection), for Intravenous Use [package insert]"},{"issue":"12","key":"pone.0327993.ref029","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1007\/s00467-013-2666-6","article-title":"Developmental changes in renal tubular transport-an overview","volume":"30","author":"J Gattineni","year":"2015","journal-title":"Pediatr Nephrol"},{"issue":"7","key":"pone.0327993.ref030","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1586\/17512433.2016.1172209","article-title":"Therapeutic drug monitoring of anti-infective agents in critically ill patients","volume":"9","author":"NGL Jager","year":"2016","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"6","key":"pone.0327993.ref031","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s00134-020-06050-1","article-title":"Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper","volume":"46","author":"MH Abdul-Aziz","year":"2020","journal-title":"Intensive Care Med"},{"issue":"5","key":"pone.0327993.ref032","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1097\/FTD.0000000000000535","article-title":"Simple LC-MS\/MS methods using core-shell octadecylsilyl microparticulate for the quantitation of total and free daptomycin in human plasma","volume":"40","author":"Y Miyadera","year":"2018","journal-title":"Ther Drug Monit"},{"issue":"4","key":"pone.0327993.ref033","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1007\/s10156-013-0559-z","article-title":"Variability of pharmacokinetic parameters in patients receiving different dosages of daptomycin: is therapeutic drug monitoring necessary?","volume":"19","author":"M Falcone","year":"2013","journal-title":"J Infect Chemother"},{"issue":"9","key":"pone.0327993.ref034","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1093\/jac\/dky072","article-title":"Association of daptomycin dosing regimen and mortality in patients with VRE bacteraemia: a review","volume":"73","author":"F Foolad","year":"2018","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"pone.0327993.ref035","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1097\/FTD.0b013e3181d3f5cb","article-title":"A rapid high-performance liquid chromatography method to measure linezolid and daptomycin concentrations in human plasma","volume":"32","author":"M Polillo","year":"2010","journal-title":"Ther Drug Monit"},{"issue":"8","key":"pone.0327993.ref036","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1093\/jac\/dkx140","article-title":"Population pharmacokinetics and dosing considerations for the use of daptomycin in adult patients with haematological malignancies","volume":"72","author":"PG Cojutti","year":"2017","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"pone.0327993.ref037","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/jcpt.13061","article-title":"Observational retrospective single-centre study in Japan to assess the clinical significance of serum daptomycin levels in creatinine phosphokinase elevation","volume":"45","author":"M Ando","year":"2020","journal-title":"J Clin Pharm Ther"},{"issue":"1","key":"pone.0327993.ref038","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/BF00429029","article-title":"Elevated serum creatine kinase MB and creatine kinase BB-isoenzyme fractions after ultra-marathon running","volume":"52","author":"TD Noakes","year":"1983","journal-title":"Eur J Appl Physiol Occup Physiol"},{"issue":"6","key":"pone.0327993.ref039","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.jiac.2023.02.012","article-title":"Pharmacokinetics of intravenous daptomycin in Japanese pediatric patients: Pharmacokinetic comparisons supporting dosing recommendations in Japanese pediatric patients","volume":"29","author":"M Ishii","year":"2023","journal-title":"J Infect Chemother"},{"key":"pone.0327993.ref040","doi-asserted-by":"crossref","DOI":"10.1016\/j.idcr.2018.e00452","article-title":"A case report and literature review of daptomycin-induced liver injury","volume":"14","author":"A Janda","year":"2018","journal-title":"IDCases"},{"issue":"8","key":"pone.0327993.ref041","doi-asserted-by":"crossref","first-page":"4902","DOI":"10.1128\/AAC.03157-14","article-title":"Case report and cohort analysis of drug-induced liver injury associated with daptomycin","volume":"58","author":"N Bohm","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"pone.0327993.ref042","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1345\/aph.1K579","article-title":"Daptomycin-induced acute renal and hepatic toxicity without rhabdomyolysis","volume":"42","author":"G Abraham","year":"2008","journal-title":"Ann Pharmacother"},{"issue":"7","key":"pone.0327993.ref043","doi-asserted-by":"crossref","first-page":"537","DOI":"10.3109\/00365548.2014.901555","article-title":"Daptomycin-induced rhabdomyolysis and acute liver injury","volume":"46","author":"ST King","year":"2014","journal-title":"Scand J Infect Dis"},{"issue":"3","key":"pone.0327993.ref044","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1177\/0897190015625403","article-title":"Possible hepatotoxicity associated with daptomycin: a case report and literature review","volume":"29","author":"Y Mo","year":"2016","journal-title":"J Pharm Pract"},{"key":"pone.0327993.ref045","volume-title":"Clinical and research information on drug-induced liver injury","author":"LiverTox","year":"2012"},{"issue":"12","key":"pone.0327993.ref046","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1086\/652767","article-title":"Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: data from a randomized trial of patients with bacteremia and endocarditis","volume":"50","author":"SM Bhavnani","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"4","key":"pone.0327993.ref047","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/00000441-198710000-00011","article-title":"Drug fever: mechanisms, maxims and misconceptions","volume":"294","author":"PA Mackowiak","year":"1987","journal-title":"Am J Med Sci"},{"issue":"4","key":"pone.0327993.ref048","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1128\/AAC.47.4.1318-1323.2003","article-title":"Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects","volume":"47","author":"BH Dvorchik","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"pone.0327993.ref049","article-title":"Seventeen cases of daptomycin-induced eosinophilic pneumonia in a cohort of patients treated for bone and joint infections: proposal for a new algorithm","volume":"9","author":"T-T Pham","year":"2022","journal-title":"Open Forum Infect Dis"},{"issue":"4","key":"pone.0327993.ref050","doi-asserted-by":"crossref","first-page":"446","DOI":"10.3390\/antibiotics10040446","article-title":"Risk factors of daptomycin-induced eosinophilic pneumonia in a population with osteoarticular infection","volume":"10","author":"L Soldevila-Boixader","year":"2021","journal-title":"Antibiotics (Basel)"},{"key":"pone.0327993.ref051","first-page":"127","article-title":"Daptomycin use for children; 27","author":"H Okui","year":"2015","journal-title":"Jpn J Infect Dis"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0327993","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T17:37:50Z","timestamp":1752773870000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0327993"}},"subtitle":[],"editor":[{"given":"Catherine A.","family":"Brissette","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,7,17]]},"references-count":51,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7,17]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0327993","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,17]]}}}